{"id":"NCT03875508","sponsor":"AbbVie","briefTitle":"A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis","officialTitle":"Plaque Psoriasis: Usability of the Risankizumab Autoinjector Combination Product in Adults With Moderate to Severe Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-04","primaryCompletion":"2020-04-24","completion":"2020-08-25","firstPosted":"2019-03-14","resultsPosted":"2021-05-11","lastUpdate":"2021-05-11"},"enrollment":108,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Risankizumab","otherNames":["ABBV-066","BI 655066"]},{"type":"DEVICE","name":"Autoinjector","otherNames":[]}],"arms":[{"label":"Risankizumab","type":"EXPERIMENTAL"}],"summary":"The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for the treatment of adult participants with moderate to severe plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Participants With an Observer Rating of Successful Participant Self-administration","timeFrame":"Day 1 and Week 28","effectByArm":[{"arm":"Risankizumab","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":26,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":108},"commonTop":["NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION"]}}